C4 Therapeutics Statistics Share Statistics C4 Therapeutics has 71.01M
shares outstanding. The number of shares has increased by 2.41%
in one year.
Shares Outstanding 71.01M Shares Change (YoY) 2.41% Shares Change (QoQ) 0.02% Owned by Institutions (%) 92.4% Shares Floating 54.36M Failed to Deliver (FTD) Shares 30,128 FTD / Avg. Volume 2.07%
Short Selling Information The latest short interest is 4.07M, so 5.73% of the outstanding
shares have been sold short.
Short Interest 4.07M Short % of Shares Out 5.73% Short % of Float 6.19% Short Ratio (days to cover) 2.19
Valuation Ratios The PE ratio is -2.37 and the forward
PE ratio is null.
C4 Therapeutics's PEG ratio is
0.06.
PE Ratio -2.37 Forward PE n/a PS Ratio 7.02 Forward PS n/a PB Ratio 1.16 P/FCF Ratio -3.82 PEG Ratio 0.06
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for C4 Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 5.71,
with a Debt / Equity ratio of 0.3.
Current Ratio 5.71 Quick Ratio 5.71 Debt / Equity 0.3 Debt / EBITDA -0.64 Debt / FCF -1.01 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $323.49K Profits Per Employee $-957.42K Employee Count 110 Asset Turnover 0.1 Inventory Turnover n/a
Taxes Income Tax 131K Effective Tax Rate -0.12%
Stock Price Statistics The stock price has increased by -57.69% in the
last 52 weeks. The beta is 2.98, so C4 Therapeutics's
price volatility has been higher than the market average.
Beta 2.98 52-Week Price Change -57.69% 50-Day Moving Average 1.83 200-Day Moving Average 2.83 Relative Strength Index (RSI) 62.57 Average Volume (20 Days) 1,457,146
Income Statement In the last 12 months, C4 Therapeutics had revenue of 35.58M
and earned -105.32M
in profits. Earnings per share was -1.52.
Revenue 35.58M Gross Profit 35.58M Operating Income -119.61M Net Income -105.32M EBITDA -103.37M EBIT -105.19M Earnings Per Share (EPS) -1.52
Full Income Statement Balance Sheet The company has 55.5M in cash and 65.76M in
debt, giving a net cash position of -10.26M.
Cash & Cash Equivalents 55.5M Total Debt 65.76M Net Cash -10.26M Retained Earnings -633.7M Total Assets 296.53M Working Capital 180.27M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -65.16M
and capital expenditures -180K, giving a free cash flow of -65.34M.
Operating Cash Flow -65.16M Capital Expenditures -180K Free Cash Flow -65.34M FCF Per Share -0.94
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -336.15% and -295.96%.
Gross Margin 100% Operating Margin -336.15% Pretax Margin -295.6% Profit Margin -295.96% EBITDA Margin -290.49% EBIT Margin -336.15% FCF Margin -183.61%
